Lexicon Pharmaceuticals (LXRX) Operating Expenses (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Operating Expenses data on file, last reported at $22.1 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $22.1 million, down 17.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $93.9 million (down 55.02% YoY), and the FY2025 annual result was $98.7 million, down 56.74% from the prior year.
• Operating Expenses advanced to $22.1 million in Q1 2026 per LXRX's latest filing, from $20.3 million in the prior quarter.
• Over five years, Operating Expenses peaked at $65.4 million in Q3 2024 and troughed at $20.3 million in Q4 2025.
• A 5-year average of $36.6 million and a median of $30.3 million in 2022 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses surged 115.24% in 2023, then plunged 65.81% in 2025.
• A 5-year view of Operating Expenses shows it stood at $30.3 million in 2022, then soared by 56.53% to $47.4 million in 2023, then climbed by 24.98% to $59.3 million in 2024, then sank by 65.81% to $20.3 million in 2025, then advanced by 9.0% to $22.1 million in 2026.
• Business Quant data shows LXRX's Operating Expenses at $22.1 million in Q1 2026, $20.3 million in Q4 2025, and $26.4 million in Q3 2025.